Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
biotech
boston blog main
indiana blog main
indiana top stories
life sciences
national blog main
raleigh-durham blog main
6
×
raleigh-durham top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
fda
national
teva pharmaceutical
amgen
fremanezumab
migraine research foundation
bristol-myers squibb
calcitonin gene-related peptide
chronic migraine
drug prices
eptinezumab
erenumab
What
approval
6
×
drug
fda
new
won
migraine
bio
class
companies
decades
developed
friday
oral
roundup
therapy
treat
acute
addresses
advanced
agency
aimmune
allergy
alnylam’s
amgen
approved
arguments
awarded
bff
big
biogen’s
biopharmaceutical
candidates
causes
commercialized
competitors
condition
conference
convo
deals
devoted
Language
unset
Current search:
approval
×
photo
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines